14-3-3 zeta蛋白过表达与他莫昔芬治疗乳腺癌耐药的关系

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1597 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的：探讨14-3-3 zeta蛋白过表达与他莫昔芬治疗乳腺癌耐药的关系。方法：采用免疫组织化学S-P法对80例雌激素受体阳性乳腺癌组织中14-3-3 zeta蛋白表达进行检测，根据14-3-3 zeta蛋白表达情况将患者分组，结合每组生存情况评价14-3-3 zeta蛋白过表达与他莫昔芬治疗乳腺癌耐药的关系。结果：癌组织中14-3-3 zeta蛋白表达总阳性率为96.25%（77/80），其中强阳性占51.25%（41/80），中等阳性占23.75%（19/80），弱阳性占21.25%（17/80）。14-3-3 zeta蛋白过表达与临床病理因素无明显相关性。随访结果显示，14-3-3 zeta蛋白过表达组患者在应用他莫昔芬治疗后更容易复发，生存期明显较短。细胞实验表明，提高乳腺癌细胞中14-3-3 zeta蛋白表达可以增强其对他莫昔芬的耐药性，反之，抑制14-3-3 zeta蛋白表达可有效提高他莫昔芬治疗的敏感性。结论：14-3-3 zeta蛋白可以作为他莫昔芬治疗乳腺癌耐药评估的生物标记物，检测乳腺癌组织内14-3-3 zeta蛋白表达可以用于评估他莫昔芬治疗乳腺癌的疗效。

	服务
	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	凌人
	凌今
	陈仲华
	刘丹丹
	赵宏圻
	柯友涛

关键词 ：乳腺肿瘤, 14-3-3 zeta, 免疫组织化学法, 他莫昔芬, 细胞凋亡

Abstract：Objective: To investigate the relationship between 14-3-3 zeta protein over-expression and tamoxifen resistance in breast cancer. Methods: The 14-3-3 zeta protein expression was detected in the cancerous tissues of 80 breast patients using immunohistochemistry. Based on the follow-up visits, survival status in both high and low 14-3-3 zeta expression groups were analyzed. Results: The total positive ratio of 14-3-3 zeta protein expression in subjects was 96.25% (77/80). Among the total positive ratio, the strong positive ratio, moderate positive ratio and weakly positive ratio were 51.25% (41/80), 23.75% (19/80) and 21.25% (17/80), respectively. The 14-3-3 zeta protein over-expression was related to clinical pathological features. According to the follow-up results, the patients in 14-3-3 zeta high expression group would cause the relapse easily for a short survival time. The results of vitro experiment indicated that the Tamoxifen resistance was enhanced after increasing the expression of 14-3-3 zeta protein. Conversely, the down-regulation of 14-3-3 zeta protein expression would reduce the tamoxifen resistance. Conclusion: As a biomarker of tamoxifen resistance, 14-3-3 zeta protein can be used for evaluating therapeutic efficacy by detecting its expression in breast cancer tissue.

Key words： breast neoplasms 14-3-3 zeta immunohistochemistry tamoxifen cell apoptosis

收稿日期: 2016-09-21

基金资助:金华市科技计划项目（2014-3-088）；浙江省医药卫生一般研究计划项目（2015KYB419）。

作者简介: 凌人（1957-），女，安徽合肥人，副主任医师。

链接本文:

https://xb.wmu.edu.cn/CN/ 或 https://xb.wmu.edu.cn/CN/Y2017/V47/I3/192

[1] Kim S I, LEE Y, SON Y, et al. Assessment of breast cancer patients’ knowledge and decisional conflict regarding tamoxifen use[J]. J Korean Med Sci, 2015, 30(11): 1604-1611.
[2] KIM J, LEE J, JANG S Y, et al. Anticancer effect of metformin on estrogen receptor-positive and tamoxifen-resistant breast cancer cell lines[J]. Oncol Rep, 2016, 35(5): 2553-2560.
[3] 罗华荣, 徐铖, 郑海红, 等. 乳腺实性乳头状癌的临床病理特征[J]. 温州医科大学学报, 2015, 45(5): 364-368.
[4] SANCHEZ-MUNOZ A, GARCIA-TAPIADOR A M, MARTINEZ-ORTEGA E, et al. Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer[J]. Clin Transl Oncol, 2008, 10(10): 646-653.
[5] 李光明, 段百芸. 托瑞米芬联合他莫昔芬应用于晚期乳腺癌治疗效果及生存质量分析[J]. 中国普通外科杂志, 2016, 25(3): 463-466.
[6] 蔡加琴, 孙红, 魏晓霞, 等. 下调长链非编码RNA H19对他莫昔芬耐药乳腺癌侵袭能力的影响[J]. 中国药学杂志,2016, 51(11): 880-883.
[7] 魏丽, 段红洁, 牛秀珑, 等. 雌激素受体β在乳腺癌他莫昔芬内分泌治疗耐药中的作用[J]. 中国肿瘤生物治疗杂志, 2015, 22(01): 52-56.
[8] 张燕青, 王连生. 基因多态对他莫昔芬疗效影响研究进展[J]. 中国药理学与毒理学杂志, 2012, 26(3): 411-414.
[9] 齐凤杰, 邸金娜, 赵树鹏. 乳腺癌中组织14-3-3σ和cyclin B1的表达及其临床意义[J]. 中国肿瘤生物治疗杂志, 2011, 18(2): 211-215.
[10] NEAL C L, YAO J, YANG W, et al. 14-3-3 zeta overex-pression defines high risk for breast cancer recurrence and promotes cancer cell survival[J]. Cancer Res, 2009, 69(8): 3425-3432.
[11] 凌人, 凌今, 倪型灏, 等. 乳腺癌RCL、TAOK1、14-3-3 zeta、ZNF706蛋白表达的临床病理意义[J]. 温州医科大学学报, 2014, 44(11): 817-821.
[12] JIN L M, HAN X H, JIE Y Q, et al. 14-3-3zeta silencing retards tongue squamous cell carcinoma progression by inhibiting cell survival and migration[J]. Cancer Gene Ther, 2016, 23(7): 206-213.
[13] MORRISON D K. The 14-3-3 proteins: integrators of diverse signaling cues that impact cell fate and cancer development[J]. Trends Cell Biol, 2009, 19(1): 16-23.
[14] CHIANG C W, HARRIS G, ELLIG C, et al. Protein phosphatase 2A activates the proapoptotic function of BAD in interleukin-3-dependent lymphoid cells by a mechanism requiring 14-3-3 dissociation[J]. Blood, 2001, 97(5): 1289-1297.
[15] LI Y, ZOU L, LI Q, et al. Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer[J]. Nat Med, 2010, 16(2): 214-218.
[16] DANES C G, WYSZOMIERSKI S L, LU J, et al. 14-3-3 zeta down-regulates p53 in mammary epithelial cells and confers luminal filling[J]. Cancer Res, 2008, 68(6): 1760-1767.
[17] HODGKINSON V C, EAGLE G L, DREW P J, et al. Biomarkers of chemotherapy resistance in breast cancer identified by proteomics: Current status[J]. Cancer Lett, 2010, 294(1): 13-24.